Need professional-grade analysis? Visit stockanalysis.com
$7.40B
N/A
673
N/A
Cytokinetics Inc (CYTK) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $66.71, up 1.97% from the previous close.
Over the past year, CYTK has traded between a low of $29.84 and a high of $70.10. The stock has gained 76.4% over this period. It is currently 123.6% above its 52-week low.
Cytokinetics Inc has a market capitalization of $7.40B.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Side-by-side comparison against top Healthcare peers.